Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors With Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion

Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology

Voyageur Pharmaceuticals Announces Collaboration With Bayer

Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial With Alberta Innovates Grant; Announces Stock Option and DSU Grants, and Proposed Issuance of Securities for Debt

Voyageur Announces Advancements on Its Barium & Iodine Contrast Media Projects

Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption

Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project

Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility

Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility

Fluor (FLR) Completes CTA Rail Project And Adds Voyageur Supply Chain Study